Cevian Capital disclosed a stake above 14% in Smith & Nephew in a late-July filing, moving the Stockholm-based activist from significant shareholder to control-threshold proximity. The firm now holds roughly £1.68bn in the London-listed medical devices company at current valuations, marking one of the largest European activist positions deployed this year. Smith & Nephew shares trade at £12.04, down 9% year-to-date, underperforming both Stryker and Zimmer Biomet by double digits.
Cevian first entered Smith & Nephew in early 2020 at a 5.1% stake, when the orthopedics and wound-care manufacturer was navigating pandemic supply-chain disruptions and margin compression in its Advanced Wound Management division. The firm has since tripled its exposure, crossing 10% in mid-2022 and now breaching 14% at a moment when Smith & Nephew's operating margin lags peers by 400 basis points. The late-July timing coincides with the company's half-year results, which showed 3.2% organic revenue growth but flat EBITDA margins at 18.1%, well behind Stryker's 24% and below internal guidance. Cevian's filings indicate no concert-party arrangements, but the 14% threshold in UK disclosure rules typically signals board engagement or structural proposals are imminent.
The escalation matters because Cevian specializes in operational turnarounds and portfolio rationalization, not proxy fights. The firm's prior work at Volvo and ThyssenKrupp involved targeted divestitures and margin expansion programs executed with management cooperation. Smith & Nephew's three-division structure—Orthopedics, Sports Medicine & ENT, and Advanced Wound Management—has long been criticized for capital inefficiency. The wound-care unit generates £1.1bn in revenue but operates at 12% EBITDA margins, roughly half the rate of the orthopedics business. A carve-out or sale of Advanced Wound Management to a pure-play wound-care operator could unlock £1.5bn in proceeds, funding share buybacks or R&D investment in higher-margin robotic surgery platforms where Smith & Nephew lags Intuitive Surgical and Stryker.
Allocators should watch for three near-term catalysts. First, Smith & Nephew's CEO Deepak Nath, who took the role in May 2022, is expected to present a revised three-year strategy at the company's Capital Markets Day, likely scheduled for Q4 2024 or Q1 2025. Second, any UK takeover-code filings from Cevian or consortium partners would appear within 28 days of crossing certain thresholds; the 14% mark often precedes formal engagement letters. Third, Smith & Nephew's upcoming Q3 trading update in late October will reveal whether margin improvement initiatives—including a $400m cost-reduction program announced in February—are gaining traction. If margins remain flat, Cevian's hand strengthens for advocating structural separation.
Cevian's move arrives as European medtech M&A dealflow reaches a seven-quarter high, with $18bn in announced transactions year-to-date, per Dealogic. Smith & Nephew's enterprise value of £13.2bn sits below the £15bn threshold that typically attracts strategic buyers like Johnson & Johnson or Medtronic, but a sum-of-parts restructuring could reposition the orthopedics core as a standalone entity trading closer to 22x forward EBITDA, matching sector comps.